https://go.evvnt.com/928130-0?pid=5248 Hyatt Regency Boston
1 Ave de Lafayette
Boston, Massachusetts 02111
Lectures & Conferences
The Gene Therapy Comparability Summit returns for the second year providing you with all the practical insights to optimize your gene therapy comparability approach.
In the context of scaling up gene therapy development to achieve commercial goals and mounting regulatory scrutiny, the 2nd Annual Gene Therapy Comparability Summit will unite large pharma and innovative biotechs to ensure you can establish comparability at every stage of development, supporting a seamless transition to the larger scales required for commercialization.
Focused specifically on enhancing your gene therapy comparability approach, this event will ensure you can maintain safety, quality, consistency and efficacy while adapting manufacturing processes, methods and platforms, to satisfy regulatory demands and avoid costly delays to clinical programs.
Across four days of curated content, incorporating detailed case studies from leading CMC, Regulatory, Analytical and Process Development experts, this is your opportunity to gain a hands-on, practical insight into exactly what it takes to execute successful comparability studies.
Drug Developer Pricing - FULL ACCESS PASS: 2 Day Conference + Workshop Day AND Comparability Day USD 4793.00
Drug Developer Pricing - 2 Day Conference + Workshop Day OR Comparability Day USD 3896.00
Drug Developer Pricing - 2 Day Conference USD 2999.00
Standard Pricing - FULL ACCESS PASS: 2 Day Conference + Workshop Day AND Comparability Day USD 5793.00
Standard Pricing - 2 Day Conference + Workshop Day OR Comparability Day USD 4896.00
Standard Pricing - 2 Day Conference USD 3999.00
Speakers: Janet Glassford, Quality Assessor, MHRA, Joshua Kidder, Director of Quality, Control Ultragenyx, Van Hoang, Head of Analytical & Quality Control, Spark Therapeutics, Ilya Shestopalov, Director & Analytical Product Lead, Bluebird Bio, Meghan Brown, Executive Director, Regulatory Affairs, CMC, Sarepta Therapeutics, Sarang Brahma, Scientist III, AskBio, Josephine Lembong, Manager, Science & Industry Affairs, Alliance for Regenerative Medicine, Nina Liu, Staff Scientist, Regeneron, Thomas Powers, Principal Scientist, Pfizer, Dawn Henke, Senior Scientific Program Manager, Standards Coordinating Body, Michael Rosconi, Associate Director, Regeneron, Santoshkumar Khatwani, Director Analytical Development, Sangamo Therapeutics, Kun Lu, Senior Staff Scientist, Regeneron, Rachael Ahern, Associate Director, Quality Control, Tessera Therapeutics, Susan Sleep, Director Analytical Development, AGTC, Alexis Behra, Quality by Design & Risk Manager, Cellectis, Cynthia N. Brysch, Head of CQA, Vertex Pharmaceuticals, Kyle Grant, Director of Vector Production, Voyager Therapeutics, Greg Hoffman, Vice President Platform & Discovery, Arbor Biotechnology, Jeremy Johnston, Director, Analytical Department, AskBio, Richard K. Burdick, Principal Consultant, Ann F Durbin, Associate Director, Assay Development, Abeona Therapeutics, Steve Soltys, VP, Process Development, Kriya Therapeutics, William Werner, Sr. Director Analytical Assay development, Astellas Gene Therapies, Allan B. Dietz, Ph.D. Director, Immune Progenitor and Stem Cell lab (IMPACT), Associate Professor of Laboratory Medicine, Associate Professor of Immunology, Mayo Clinic, Arnaud Deladeriere, Director of Process Development, Triumvira, Markus Haindl, Head Gene Therapy Technical Development, Roche, Omar Tounekti, Manager, Gene Therapies Division in the Biologic and Radiopharmaceutical Drugs Directorate (BRDD), Health Canada, Yoko Momonoi Head, Global CMC Regulatory Affairs, Takeda, Wyatt Technologies, Qiagen, Touchlight AAV